CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV): EFFICACY OF DIFFERENT ANTIEMETIC REGIMENS ACROSS EMETOGENIC RISK LEVELS
DOI:
https://doi.org/10.37762/jgmds.13-1.820Keywords:
Antiemetic Therapy, Nausea, Vomiting Triplet Regimen, Domperidone, MetoclopramideAbstract
ABSTRACT
OBJECTIVES
This audit aimed to determine the efficacy of different antiemetic regimens across emetogenic risk levels in managing chemotherapy-induced vomiting and nausea.
METHODOLOGY
This retrospective cross-sectional clinical audit was conducted at the Department of Oncology, Northwest General Hospital, Peshawar, from Jan to December 2024, involving 369 patients presenting for chemotherapy. Patients' demographic and clinical characteristics were collected from medical records or directly from patients regarding their last chemotherapy experience. Patients were receiving three antiemetic regimens: Triplet antiemetic regimen (Aprepitant + Ondansetron + Dexamethasone), Triplet regimen + Metoclopramide, and Triplet regimen + domperidone. The incidence of vomiting and nausea post-chemotherapy was assessed using a structured questionnaire. SPSS-25 was used for data analysis. The chi-square test was applied with a 5% significance level.
RESULTS
Out of 369 cancer patients receiving chemotherapy, the median age was 54 years (IQR=18), ranging from 14 to 87 years, with a majority being female 209(56.6%). Vomiting was reported in 57(15.4%) patients, primarily occurring within the first three days, 33(58%), peaking on day two. Most cases were mild (1-2 episodes/day) in 39(68%) patients, with severe vomiting (≥10 episodes/day) occurring in only 3(5.3%) patients. Nausea was reported by 111(30.1%) patients. Digestive system cancers 81(22%) and breast cancer 78(21.1%) were the most common cancer types. Vomiting was significantly associated with moderate-risk chemotherapy (p<0.0001), where the triplet + metoclopramide group had the highest incidence. (29/42 cases)(69%). Overall, patients in the triplet + domperidone group had a lower incidence of nausea (49/111)(44%) and vomiting (22/57)(38.6%) compared to the triplet + metoclopramide group, though differences were not always statistically significant (p=0.17 for vomiting, p = 0.008 for nausea). Vomiting was significantly associated with antiemetic regimen selection in digestive system cancers (p<0.0001) and blood cancers (p=0.032), whereas nausea was significantly associated with antiemetic regimen selection in digestive system cancers (p<0.0001).
CONCLUSION
The triplet + domperidone regimen was associated with lower observed rates of chemotherapy-induced nausea and vomiting. However, overall differences between regimens were not statistically significant (except in the moderate emetogenic risk group), suggesting that the treatments were generally comparable in effectiveness
Downloads
Metrics
References
Tilsed CM, Fisher SA, Nowak AK, Lake RA, Lesterhuis WJ. Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. Front Oncol. 2022 Jul 29;12:960317. doi:10.3389/fonc.2022.960317 DOI: https://doi.org/10.3389/fonc.2022.960317
van den Boogaard WM, Komninos DS, Vermeij WP. Chemotherapy side-effects: not all DNA damage is equal. Cancers (Basel). 2022 Jan 26;14(3):627. doi:10.3390/cancers14030627 DOI: https://doi.org/10.3390/cancers14030627
Wang Y, Wu X, Ren Z, Li Y, Zou W, Chen J, Wang H. Overcoming cancer chemotherapy resistance by the induction of ferroptosis. Drug Resist Updat. 2023 Jan 1;66:100916. doi:10.1016/j.drup.2023.100916 DOI: https://doi.org/10.1016/j.drup.2022.100916
Kim SD, Kwag EB, Yang MX, Yoo HS. Efficacy and safety of ginger on the side effects of chemotherapy in breast cancer patients: systematic review and meta-analysis. Int J Mol Sci. 2022 Sep 24;23(19):11267. doi:10.3390/ijms231911267 DOI: https://doi.org/10.3390/ijms231911267
Majem M, de Las Peñas R, Virizuela JA, Cabezón-Gutiérrez L, Cruz P, Lopez-Castro R, et al. SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2021). Clin Transl Oncol. 2022 Apr;24(4):712–23. doi:10.1007/s12094-021-02746-2 DOI: https://doi.org/10.1007/s12094-022-02802-1
Piechotta V, Adams A, Haque M, Scheckel B, Kreuzberger N, Monsef I, et al. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis. Cochrane Database Syst Rev. 2021 Nov;11:CD012775. doi:10.1002/14651858.CD012775.pub2 DOI: https://doi.org/10.1002/14651858.CD012775.pub2
Aapro M, Scotté F, Escobar Y, Celio L, Berman R, Franceschetti A, Bell D, Jordan K. Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. The Oncologist. 2021 Jun;26(6):e1073–82. doi:10.1002/onco.13725 DOI: https://doi.org/10.1002/onco.13716
Filetti M, Lombardi P, Giusti R, Falcone R, Scotte F, Giannarelli D, et al. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. Cancer Treat Rev. 2023 Apr 1;115:102512. doi:10.1016/j.ctrv.2023.102512 DOI: https://doi.org/10.1016/j.ctrv.2023.102512
Zhang M, Guo QL, Zhang TT, Fu M, Bi HT, Zhang JY, Zou KL. Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: a meta-analysis. Medicine (Baltimore). 2023 Nov 24;102(47):e35952. doi:10.1097/MD.0000000000035952 DOI: https://doi.org/10.1097/MD.0000000000035952
Vaid AK, Gupta S, Doval DC, Agarwal S, Nag S, Patil P, et al. Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective. Front Oncol. 2020 Mar 27;10:400. doi:10.3389/fonc.2020.00400 DOI: https://doi.org/10.3389/fonc.2020.00400
Benlahrech ZB, Hail K, Khireddine M, Haria FZ, Benghanem L. Prevalence of chemotherapy-induced nausea and vomiting: an Algerian study. Eur J Med Health Res. 2024 Mar 1;2(2):239–41. doi:10.59324/ejmhr.2024.02.239 DOI: https://doi.org/10.59324/ejmhr.2024.2(2).29
Fernández-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A, et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life. Support Care Cancer. 2012 Dec;20(12):3141–8. doi:10.1007/s00520-012-1448-1 DOI: https://doi.org/10.1007/s00520-012-1448-1
van der Vorst MJ, Toffoli EC, Beusink M, van Linde ME, van Voorthuizen T, Brouwer S, et al. Metoclopramide, dexamethasone, or palonosetron for prevention of delayed chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy (MEDEA): a randomized, phase III, noninferiority trial. The Oncologist. 2021 Jan;26(1):e173–81. doi:10.1002/onco.13579 DOI: https://doi.org/10.1634/theoncologist.2020-0305
Huang JQ, Zheng GF, Chan GC, Karlberg J, Lam SK, Wong BC. Efficacy of current antiemetic treatments for preventing delayed chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials. Clin Res Regul Aff. 2004 Jan 1;21(3–4):191–212. doi:10.1081/CRP-200040978 DOI: https://doi.org/10.1081/CRP-200049997
Simhadri S, Dayyala S, Musinipally AD, Guram L, Madavi M, Kancha R, et al. Generic netupitant plus palonosetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting in cancer patients receiving highly or moderately emetogenic chemotherapy: a retrospective study. South Asian J Cancer. 2024 Apr 15;13(2):123–9
Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H, et al. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013 Sep;21(9):2575–81. doi:10.1007/s00520-013-1821-3 DOI: https://doi.org/10.1007/s00520-013-1835-2
Kaushal P, Atri R, Soni A, Kaushal V. Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients. ecancermedicalscience. 2015 Aug 25;9:567. doi:10.3332/ecancer.2015.567. DOI: https://doi.org/10.3332/ecancer.2015.567
Płużański A, Kalinka-Warzocha E, Łacko A, Rubach M. Prevention of chemotherapy-induced nausea and vomiting—standards versus clinical practice. Oncol Clin Pract. 2016;12(4):153–7. doi:10.5603/OCP.2016.0018
Hsieh RK, Chan A, Kim HK, Yu S, Kim JG, Lee MA, et al. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer. 2015 Jan;23(1):263–72. doi:10.1007/s00520-014-2372-3 DOI: https://doi.org/10.1007/s00520-014-2373-2
Hiremath SB, Devendrappa SL. The efficacy and safety of adding olanzapine to triple-drug regimen to prevent chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of RCTs. Pharmacol Clin Pharm Res. 2022 Sep;7(2):45–54. doi:10.31069/pcpr.2022.07.02.005 DOI: https://doi.org/10.15416/pcpr.v7i2.37936
Roeland E, Aapro MS, Schwartzberg LS. Advances in the management of chemotherapy-induced nausea and vomiting: new data from recent and ongoing trials. Clin Adv Hematol Oncol. 2015 Oct;13(10 Suppl 10):1–4
Tian SC, Yang J, Li X, Huang RX, Chen J. Bibliometric and visual analysis of chemotherapy-induced nausea and vomiting (2004–2023). Front Oncol. 2024 Apr 24;14:1377486. doi:10.3389/fonc.2024.1377486 DOI: https://doi.org/10.3389/fonc.2024.1377486
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Muhammad Umer Khayyam Azam, Bushra Haider, Nadia Qazi
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
